Navigation Links
Reportlinker Adds Stem Cell Therapeutics Markets Report
Date:9/24/2009

NEW YORK, Sept. 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

Stem Cell Therapeutics Markets

http://www.reportlinker.com/p0116170/Stem-Cell-Therapeutics-Markets.html

Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S. Congress has also indicated a desire to move forward with stem cell research. The momentum in two branches of American government, along with scientific developments and the competition of world markets presages good market conditions for stem cell research.

With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.

While companies have found opportunity outside the U.S., President Bush's seven year limitations on embryonic stem cell research in the U.S. has limited the U.S. market. Changes in U.S. policy should open up U.S. markets. For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells Therapeutics Markets. Kalorama analyst Alison Sahoo has built models to determine the best case and most likely case scenarios for therapeutic markets for stem cells in the coming years.

This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:

  • Cardiovascular disease

  • Lung disease

  • Arthritis

  • Incontinence

  • Osteoporosis

  • Diabetes

  • Cancer

  • Orthopedics

  • Infertility

  • Alzheimer's disease

  • Burns (severe)

  • Lupus

  • Parkinson's disease

  • Liver failure

  • Multiple sclerosis

  • Critical limb ischemia

  • Crohn's disease

  • Sickle cell disease

  • Multiple myeloma

  • NH lymphoma

  • Leukemia

This report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:

  • Aastrom Biosciences

  • Advanced Cell Technologies

  • Brainstorm Cell Therapeutics

  • Celegene

  • ES Cell International

  • Medistem

  • Neostem

  • Opexa Therapeutics

  • Osiris Therapeutics

  • Plureon

  • Regenetech

  • Revivicor

  • Stem Cell Sciences

  • StemLifeLine

  • ThermoGenesis

  • VetCell Bioscience

CHAPTER ONE: EXECUTIVE SUMMARY

Recent Developments

Introduction

Current Stem Cell Therapies

Developmental Stem Cell Therapies

Issues in Stem Cell Research

Stem Cell Forecasts

Market Forecast

The Promise of Stem Cells in Medical Treatment

Types of Stem Cells

Embryonic Stem Cells

Important Developments in ES Cell Research

Adult Stem Cells

Important Developments

Scope and Methodology

CHAPTER TWO: CURRENT STEM CELL THERAPIES

Cancer

Leukemia

Gene Therapy

Multiple Myeloma

Non-Hodgkin's Lymphoma Noncancerous Diseases

Aplastic Anemia

Immunodeficiency

Lupus

Sickle Cell Disease

Other Conditions

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES

Alzheimer's Disease

Arthritis

Burns

Cancer

Cardiovascular Conditions

Critical Limb Ischemia

Crohn's Disease

Diabetes

Incontinence

Infertility

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson's Disease

Sickle Cell Disease

CHAPTER FOUR: STEM CELL MARKET FORECASTS

Best Case

Forecasts By Disease Area

Alzheimer's Disease

Arthritis

Burns

Cancer,

Cardiovascular Conditions

Critical Limb Ischemia

Crohn's Disease

Diabetes,

Incontinence

Infertility,

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson's Disease

Sickle Cell Disease

Most Likely Case

Forecasts By Disease Area

Alzheimer's Disease

Arthritis

Burns

Cancer,

Cardiovascular Conditions

Critical Limb Ischemia

Crohn's Disease

Diabetes,

Incontinence

Infertility,

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson's Disease

Sickle Cell Disease

CHAPTER FIVE: COMPANY PROFILES

Aastrom Biosciences

Advanced Cell Technologies

Athersys

Brainstorm Cell Therapeutics

Celegene

ES Cell International

Medistem

MultiCell Technologies, Inc.

Neostem

Nephros Therapeutics, Inc.

Opexa Therapeutics

Osiris Therapeutics

Plureon

Regenetech

Revivicor

Stem Cell Sciences

ThermoGenesis

VetCell Bioscience

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020

CHAPTER TWO: CURRENT STEM CELL THERAPIES

Table 2-1: Types of Leukemia, 2007

CHAPTER THREE: DEVELOPMENTAL STEM CELL THERAPIES

Table 3-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007

Table 3-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020

Table 3-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020

Table 3-4: Types and Features of Urinary Incontinence, 2007

Table 3-5: Types and Causes of Male Infertility, 2007

Table 3-6: Common Diseases of the Lungs, 2007

CHAPTER FOUR: STEM CELL MARKET FORECASTS

Table 4-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007

Table 4-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer's Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn's Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson's Disease, Sickle Cell Disease)

Table 4-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 - 2020(Alzheimer's Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn's Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson's Disease, Sickle Cell Disease)

Table 4-4: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 - 2020(Alzheimer's Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn's Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson's Disease, Sickle Cell Disease)

Table 4-5: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020(Alzheimer's Disease, Arthritis, Burns, Cancer, Cardiovascular Conditions, Critical Limb Ischemia, Crohn's Disease, Diabetes, Incontinence, Infertility, Liver Failure, Lung Disease, Multiple Sclerosis, Orthopedics, Osteoporosis, Parkinson's Disease, Sickle Cell Disease)

CHAPTER FIVE: COMPANY PROFILES

Table 5-1: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007

To order this report:

Stem Cell Therapeutics Markets

http://www.reportlinker.com/p0116170/Stem-Cell-Therapeutics-Markets.html

More market research reports here!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
2. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
3. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
4. Reportlinker Adds Membrane Bioreactors Report
5. Reportlinker Adds Nanoporous Materials Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanomedicine Report
8. Reportlinker Adds Proteomics: Technologies and Global Markets Report
9. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
10. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
11. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DUBLIN , Feb. 16, 2017 ... the "Synthetic Biology: Global Markets" report to ... ... synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis ... DNA synthesis and assembly, genome editing, bioinformatics and specialty ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... Feb. 16, 2017  Rhythm, a biopharmaceutical ... deficiencies that result in life-threatening metabolic disorders, ... million mezzanine round of financing with existing ... Capital, New Enterprise Associates, Pfizer Venture Investments, ... healthcare investment fund. Rhythm will use the ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):